The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

KIT is detected in a variety of cells, also in acute leukemia. Inhibition of wild-type KIT is not always satisfactory. The aim of this work was to evaluate the frequency of the most common KIT mutations in acute myeloid leukemia (AML) and determine the correlation between mutation and expression level. Samples were obtained from 75 patients with AL. CD117 presence was shown in 45 of 51 patients with AML and in 1 of 16 patients with acute lymphocytic leukemia (ALL). Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia. Other genetic changes were found in 15 of 57 samples with AML: polymorphisms Met541Leu in 14% of cases, Lys546Lys in 7% and 1 case of acute biclonal leukemia, Ile798Ile in 5.3% of cases, Met541Leu in 1 acute biphenotypic leukemia and in 6.3% of ALL. Polymorphism Lys546Lys was also shown in 1 case of acute biclonal leukemia. Nonsilent genetic changes were detected in a total of 23% cases with core binding factor leukemia. There was no statistical significance between KIT expression and genetic changes. There was no correlation between the incidence and types of KIT mutations and its expression on cells in AML.

[1]  S. Corey,et al.  Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias , 2010, Clinical Cancer Research.

[2]  M. Heuser,et al.  An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. , 2010, Leukemia research.

[3]  S. Baker,et al.  Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia , 2008, Molecular Cancer Therapeutics.

[4]  H. Döhner,et al.  Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib , 2007, Cancer.

[5]  C. Auewarakul,et al.  C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia , 2006, Annals of Hematology.

[6]  H. Kantarjian,et al.  Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. , 2005, Leukemia research.

[7]  H. Mitsuya,et al.  Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation , 2005, Leukemia.

[8]  J. Kononen,et al.  Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Marx,et al.  Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.

[10]  Yong-kun Wei,et al.  C-kit gene mutation in human gastrointestinal stromal tumors. , 2004, World journal of gastroenterology.

[11]  E. Estey,et al.  C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. , 2004, Leukemia research.

[12]  I. Bernstein,et al.  Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. , 2003, Blood.

[13]  H. Moch,et al.  KIT in ovarian carcinoma: disillusion about a potential therapeutic target. , 2003, Journal of the National Cancer Institute.

[14]  H. Kantarjian,et al.  Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders , 2003, Cancer.

[15]  A. Marx,et al.  Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. , 2003, Blood.

[16]  L. Ashman,et al.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.

[17]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[18]  L. Nelson,et al.  Investigation of KIT gene mutations in women with 46,XX spontaneous premature ovarian failure , 2002, BMC women's health.

[19]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[20]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[21]  R. Arceci,et al.  Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells , 2001, Leukemia & lymphoma.

[22]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[23]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[24]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[25]  N. Sepp,et al.  Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.

[26]  T. Suda,et al.  Analysis of C-KIT, TIE and HTK expression on leukemic cells using flow cytometry: a preliminary report. , 1998, Leukemia research.

[27]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[28]  L. Larizza,et al.  A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene. , 1996, Molecular and cellular probes.

[29]  G. Schmitz,et al.  Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. , 1996, Leukemia.

[30]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Satow,et al.  c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders , 1995, British journal of haematology.

[32]  W. Gerald,et al.  Expression of c-kit and kit ligand proteins in normal human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  M. Reuss-Borst,et al.  AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.

[34]  E. Huang,et al.  The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. , 1993, Development (Cambridge, England). Supplement.

[35]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[36]  A. Ullrich,et al.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. , 1992, Cancer research.

[37]  R. Spritz,et al.  Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. , 1992, Oncogene.

[38]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.

[39]  L. Ashman,et al.  Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. , 1991, Blood.

[40]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[41]  L. Ashman,et al.  Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues , 1987, Immunology and cell biology.

[42]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[43]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[44]  L. Ashman,et al.  Expression of the YB 5 . BS Antigen ( cki t proto-oncogene product ) in Normal Human Bone Marrow , 2003 .

[45]  R. Ward,et al.  c‐kit mutations in gastrointestinal stromal tumours , 2002, Pathology.

[46]  E. Jaffe,et al.  Extranodal peripheral T-cell and NK-cell neoplasms. , 1999, American journal of clinical pathology.

[47]  P. Musto,et al.  CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. , 1998, Haematologica.

[48]  A. Órfão,et al.  The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias , 1998 .

[49]  E. Thiel,et al.  Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. , 1997, Haematologica.

[50]  D. Catovsky,et al.  C-kit receptor (CD117) expression in acute leukemia. , 1996 .

[51]  L. Ashman,et al.  Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. , 1994, Leukemia.

[52]  C. Juttner,et al.  Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. , 1988, Leukemia research.